The Cool Stuff Only Happens at Scale

What challenges do first-time founders or tech founders encounter when building companies in the bio space, and how do they differ from traditional tech companies? In this hallway-style conversation episode of the a16z Podcast (originally recorded as a video), a16z bio team general partners Vijay Pande and Jorge Conde, with Jeff Low discuss the mindset shifts involved in building bio (particularly therapeutics) companies. They cover everything from different paths to market and different partnerships (including pharma) to different timelines and milestones for validating the product and business itself. But how do we get to a common language that bridges the worlds of tech and bio?

10 Maj 201827min

with Bryan Caplan (@bryan_caplan), Marc Andreessen (@pmarca), and Sonal Chokshi (@smc90) Signaling and credential inflation -- not learning -- can explain why education pays in the labor market, and why we shouldn't invest (any more) in it, argues Bryan Caplan, economics professor at George Mason University and author of the book The Case Against Education: Why the Education System is a Waste of Time and Money. But is it really... a waste of time and money? Doesn't education have other benefits at least, like "learning to learn"; or sorting personality traits for employers at least; or helping developing economies even? And isn't it interesting that all the people (not just Caplan, but many in Silicon Valley and elsewhere) who argue against education are in fact, ahem, educationally credentialed themselves? This episode of the a16z Podcast, hosted by Marc Andreessen with Sonal Chokshi, takes on Caplan's "cynical idealist" take to probe both the cynical (problems, realities) and idealist (implications, solutions) aspects of education, no matter one's politics. And finally, where does tech (and a bit of sci-fi) come in??

9 Maj 201844min

with Atul Butte (@atulbutte), Daphne Koller (@daphnekoller), and Vijay Pande (@vijaypande) Whether you’re an academic seeking to move out of research and into industry, or simply interested in working at a bio startup, this episode of the a16z Podcast is for you. It covers everything from how to build a brand in the space when you don’t have one to how the bio and how the healthcare startup ecosystem is different from traditional tech (or traditional pharma), to how to choose the right co-founder -- or even identify what problems to solve and build a company around. The discussion (which is based on a recent event at Andreessen Horowitz) features Atul Butte, Distinguished Professor and Director of the Institute for Computational Health Sciences at UCSF; and Daphne Koller, founder and CEO of insitro (former professor at Stanford, co-founder of Coursera); in conversation with a16z bio team general partner Vijay Pande. Together, they provide practical how-to's -- for those coming from machine and deep learning backgrounds, but also for anyone, really -- for how to break into the bio space. The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments and certain publicly traded cryptocurrencies/ digital assets for which the issuer has not provided permission for a16z to disclose publicly) is available at https://a16z.com/investments/. Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see https://a16z.com/disclosures for additional important information.

2 Maj 201841min

with Ray Dalio (@raydalio), Alex Rampell (@arampell), and Sonal Chokshi (@smc90) Can one really apply the lessons of history and of the past to the present and the future, as a way to get what they want out of life? By deeply understanding cause-effect relationships -- clearly expressed, shared with others, overlaid with data, back-tested, modified -- you can build a set of principles/algorithms/recipes for dealing with the realities of your life, observes Ray Dalio in this episode of the a16z Podcast (in conversation with a16z general partner Alex Rampell and Sonal Chokshi). Dalio's book Principles: Life and Work originated as an internal company document that was posted online years ago and has been shared widely since; he is the founder, chairman, and co-chief investment officer of Bridgewater Associates -- one of the top five private companies in the U.S., which manages over $150 billion and has made more money for clients than any other hedge fund. "Is this is a duck, how do I deal with ducks; or this is a species I haven't seen before, and how do I deal with that?" In other words, when you see a particular thing coming over and over again, you can know what you're seeing and how to act on it. But what about timing, which is a huge factor when it comes to making various bets and decisions in both work and life? And what if a phenomenon is entirely new and hasn't been seen before (is there such a thing), and also, how do we avoid an overly pattern-matching/ pattern-recognition trap? Having a framework can still help -- even if the phenomena don't have a clear set of rules like chess -- because we can understand why things might be different. Knowing that is important, argues Dalio. The conversation covers everything from the differences between private and public investing, and between startups and big companies -- to how people, teams, organizations, and even nation-states can evolve through principles like "believability-weighted idea meritocracies" and more. But... can adults really change? What are the differences between the two you's, and between closed-minded and open-minded people, and how do they play out across the roles of a "teacher", "student", or "peer" in organizations of varying scale? It's not as obvious as you might think, and knowing how you know -- and what we don't know -- can help.

21 Apr 201849min

Many of the healthcare headlines lately have been about consolidation in the industry: Walmart and Humana; Aetna and CVS; Amazon, JP Morgan, and Berkshire Hathaway. But what does it all mean for patients, and startups -- Will it decrease costs? What opportunities may arise as a result? In this quick hallway-style conversation, originally recorded as a video, some of the partners on the a16z bio team (Jorge Conde and Vijay Pande in conversation with Jeffrey Low) discuss what's going on as we see more and more vertical integration across the healthcare value chain.

16 Apr 20188min

The creation of each new biotechnology enables a tool, a therapy, or a diagnostic: a molecule, a protein, an app, a platform. And the process underneath isn't just complex in the science and engineering of it, but in the go to market. So who are the stakeholders in this process? In this podcast (which was originally recorded as a video), a16z bio fund general partners Jorge Conde and Vijay Pande give a quick hallway-conversation style overview on the stakeholders -- as well as what the process is from inception to approval to market; how do go-to-market models differ; and what should founders know at the beginning of each path.

16 Apr 20187min

Hypothesis, test, revise -- that's science. Engineering, however, doesn't quite go that way: You have parts you know and understand (like legos), and then you use those parts to design and build something (like bridges). But the key is that when science -- time-consuming, unpredictable, slow, expensive -- becomes more like engineering -- faster, more methodical/repeatable, cheaper -- you can do new things... or do them in better ways. This means engineering disciplines like mechanical engineering, electrical engineering, computer science, and materials science can carry over to biology. But the question is HOW does this happen, and how can entrepreneurs apply principles from one discipline to another? How does it affect a healthcare startup's go to market, and how might a shift like this affect the healthcare industry as a whole? Vijay Pande and Jorge Conde (general partners on our bio fund) reflect on all this and more in this hallway-style conversation episode of the a16z Podcast, which was originally recorded as a video.

16 Apr 201822min

with Lisa Hawke (@ldhawke) and Steven Sinofsky (@stevesi) Given concern around data breaches, the EU Parliament finally passed GDPR (General Data Protection Regulation) after four years of preparation and debate; it goes into enforcement on May 25, 2018. Though it originated in Europe, GDPR is a form of long-arm jurisdiction that affects many U.S. companies -- including most software startups, because data collection and user privacy touch so much of what they do. With EU regulators focusing most on transparency, GDPR affects everything from user interface design to engineering to legal contracts and more. That's why it's really about "privacy by design", argues former environmental scientist and lawyer Lisa Hawke, who spent most of her career in regulatory compliance in the oil industry and is now Vice President of Security and Compliance at a16z portfolio company Everlaw (she also serves as Vice Chair for Women in Security and Privacy). And it's also why, observes a16z board partner Steven Sinofsky, everyone -- from founders to product managers to engineers and others -- should think about privacy and data regulations (like GDPR, HIPAA, etc.) as a culture... not just as "compliance".  The two break down the basics all about GDPR in this episode of the a16z Podcast -- the why, the what, the how, the who -- including the easy things startups can immediately do, and on their own. In fact, GDPR may give startups an edge over bigger companies and open up opportunities, argue Hawke and Sinofsky; even with fewer resources, startups have more organizational flexibility, if they're willing to put in the work.  for links mentioned in this episode (and other resources), please go to: https://a16z.com/2018/04/12/gdpr-why-what-how-for-startups/

12 Apr 201835min